Niemann-Pick Disease / ASMD and the SMPD1 Gene: What a Carrier Result Really Means, Plus the New Enzyme Therapy (US/Canada Guide)

Niemann-Pick Disease / ASMD and the SMPD1 Gene: What a Carrier Result Really Means, Plus the New Enzyme Therapy (US/Canada Guide)

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Niemann-Pick disease types A and B, now grouped as acid sphingomyelinase deficiency (ASMD), is an autosomal-recessive condition, so being a single SMPD1 carrier does not mean you will develop it. A landmark change arrived in 2022: the randomized ASCEND trial supported the first disease-specific enzyme therapy, olipudase alfa (Xenpozyme), which the FDA approved on 2022-08-31 for the non-brain manifestations of ASMD. But that drug does not cross into the brain and does not treat the neurological disease of the severe infantile type A form. A direct-to-consumer carrier report is a screening flag, not a diagnosis, and confirming it with a clinical lab and a genetic counselor is the concrete next step.

What you’ll learn:

• What a “carrier” result for the SMPD1 gene does and does not mean for you and your children.
• How to turn a carrier finding into real numbers, like a 25% per-pregnancy risk only when both partners carry a variant.
• Why type A/B (SMPD1) is a genetically different disease from Niemann-Pick type C.
• What the new drug olipudase alfa (Xenpozyme) can treat, and the important thing it cannot.

How Niemann-Pick / ASMD Is Inherited: the SMPD1 Gene and Autosomal-Recessive Transmission

Acid sphingomyelinase deficiency (ASMD) is an inherited metabolic disorder. Historically it was split into Niemann-Pick disease type A and type B, but experts now treat them as one disease that spans a range of severity. It is caused by pathogenic variants in the SMPD1 gene on chromosome 11p15.4, which builds a lysosomal enzyme called acid sphingomyelinase, or ASM.

Here is what that enzyme normally does. A lysosome is the cell’s recycling center, and ASM breaks down a fatty molecule called sphingomyelin inside it. When ASM activity is too low, sphingomyelin piles up in the lysosomes of macrophages and other cells. This buildup spreads across several organs and, in severe cases, the brain:

• Spleen and liver, which often enlarge as fatty material collects.
• Lungs, where buildup can cause progressive lung disease.
• Bone marrow, which affects blood cell counts.
• Brain, but only in the severe infantile form.

This process creates the fat-laden “foam cells” that doctors see under a microscope. Think of it like a clogged recycling bin that keeps overflowing because the sorter is broken.

The gene follows strict autosomal-recessive inheritance. A person needs two pathogenic SMPD1 variants, one from each parent, to develop the disease. A person with only one variant is an unaffected carrier with no symptoms. The severity depends partly on which variants you have. Certain variants associate with the severe infantile type A form, while the recurrent p.Arg610del (also written R608del) variant is linked to the milder chronic visceral type B form.

One point prevents a lot of confusion. Niemann-Pick disease type C is a different disease. It comes from variants in the NPC1 or NPC2 genes, which handle cholesterol movement, not from SMPD1. Type C shares only the historical name; its genetics and treatment are separate. A board-certified medical geneticist or a genetic counselor (you can find one through NSGC.org) can confirm which condition and which SMPD1 variants apply to your family.

Section recap: ASMD (Niemann-Pick types A and B) appears only with two pathogenic SMPD1 variants, so a single carrier stays healthy; type C is a genetically separate NPC1/NPC2 disease that shares only the old name.

Risk Magnitude: What an SMPD1 Carrier Result Means Versus Lifetime Risk of Disease

Carrier status is, on its own, low-stakes for your own health. A single carrier of one SMPD1 variant never develops ASMD. The disease itself is rare in the general population, with combined type A and type B incidence estimated at roughly 1 in 250,000 births. In everyday terms, out of 250,000 babies, about 1 is expected to be affected.

That average hides a big difference between communities. In people of Ashkenazi Jewish background, three founder variants account for roughly 90% of the mutant alleles behind type A. Carrier frequency for those variants is therefore much higher there than in the general population. Ancestry can shift the odds substantially, which is why family history and background matter to the conversation.

The number that actually matters for a carrier is reproductive risk, and it depends entirely on the other parent. If only one partner is a carrier, no child can develop the disease. When both partners carry a pathogenic SMPD1 variant, each pregnancy follows fixed proportions that repeat independently every time:

Outcome for each pregnancy	Chance	In everyday terms
Affected child (two variants)	25%	About 25 out of 100
Unaffected carrier child (one variant)	50%	About 50 out of 100
Unaffected non-carrier child (no variant)	25%	About 25 out of 100

Think of it like flipping two coins each pregnancy: the odds reset every time, so a past outcome does not change the next one.

One caution keeps this honest. Direct-to-consumer panels, such as a 23andMe SMPD1 type A report, test only a limited set of variants, often just the common Ashkenazi type A variants. So a “no variant detected” result does not fully rule out carrier status. This is especially true for people who are not of Ashkenazi background or who carry a type B-associated variant. A genetic counselor can help weigh these numbers before you treat them as certainty.

Section recap: A single carrier will not develop ASMD; the 25% per-pregnancy risk applies only when both partners carry a pathogenic SMPD1 variant, and Ashkenazi founder variants raise carrier frequency far above the roughly 1-in-250,000 general incidence.

Testing Options in the US and Canada: DTC Carrier Reports vs. Clinical Enzyme and Gene Testing

There is a real difference between a screening report and a diagnosis. Consumer carrier reports from services like 23andMe or AncestryDNA check only a limited SMPD1 variant panel, and they are screening tools, not diagnostic tests. An abnormal result should be confirmed in a CLIA-certified clinical laboratory in the US, or an accredited lab in Canada, before any medical decision.

Clinical testing follows a clearer, two-step path:

• Step 1 — enzyme assay. The biochemical hallmark is a deficient acid sphingomyelinase enzyme-activity test, measured in peripheral-blood leukocytes or a dried blood spot.
• Step 2 — gene sequencing. That enzyme result is confirmed by SMPD1 gene sequencing to identify the two pathogenic variants.

Expanded carrier panels and full-gene sequencing are offered by clinical labs such as Invitae and GeneDx. Think of the enzyme test as a smoke alarm and the sequencing as the inspector who finds the exact cause.

Newborn screening is an important gap to understand. Unlike some metabolic conditions, ASMD is not on the US Recommended Uniform Screening Panel (RUSP), and it is not part of routine newborn screening in the US or Canada. In practice, that means ASMD is usually found through carrier screening, family history, or symptoms, not through a newborn screen. So a DTC report or a family history is often the first clue rather than a hospital test at birth. An NSGC-certified genetic counselor (NSGC.org) is a valuable partner before you decide which test to pursue.

Section recap: Consumer reports are limited, screening-only panels that must be confirmed by an enzyme assay plus SMPD1 sequencing in a clinical lab; ASMD is not on the US RUSP and is not caught by routine US or Canadian newborn screening.

Interpreting Your Result: Diagnostic, Carrier, or Variant of Uncertain Significance, and Which “Type”

Results fall into a few categories, and the labels matter. The interpretive ladder works like this:

• Diagnosis: deficient acid sphingomyelinase enzyme activity plus two pathogenic SMPD1 variants, with consistent clinical and imaging findings.
• Carrier: one pathogenic variant with normal enzyme activity — this means carrier status, not illness.
• Variant of uncertain significance (VUS): a change whose link to disease is not established; guidelines say it must not be treated as a diagnosis.

There is an important limit built into a single-gene report. A DTC SMPD1 result cannot, by itself, tell carrier status apart from affected status. That distinction requires an enzyme (biochemical) test, not a gene report alone. So a single-gene panel can flag a variant but cannot confirm or exclude the disease on its own.

Genotype also only partly predicts the “type.” Certain SMPD1 variants associate with the severe infantile type A form, while the p.Arg610del (R608del) variant associates with the milder chronic visceral type B form. But this genotype-phenotype correlation is imperfect, so prognosis should come from specialists, not from a DTC label. Published standards give laboratories a shared five-tier system: pathogenic, likely pathogenic, VUS, likely benign, and benign. This is exactly the kind of result an NSGC-certified genetic counselor (NSGC.org), working with a metabolic or lysosomal-disease specialist, is trained to interpret.

Section recap: A diagnosis needs deficient enzyme activity plus two pathogenic variants; a single variant means carrier status, a VUS is not a diagnosis, and a single-gene DTC report cannot tell carrier from affected without enzyme testing.

Prevention, Early Detection, and Management for At-Risk Families

You cannot change an inherited SMPD1 genotype, so the useful levers are early diagnosis, careful monitoring, and reproductive planning. For someone diagnosed with ASMD, care centers on tracking the organs the disease affects. Consensus guidance recommends baseline and ongoing assessment of several organ systems. A long-running natural-history cohort of 103 type B patients confirmed which problems to watch for. Those problems map onto a clear surveillance panel:

• Spleen and liver size — both often enlarge.
• Blood counts — low counts can come from an overactive spleen (hypersplenism).
• Lipid profile — blood fats are often abnormal.
• Lung function with chest imaging — progressive interstitial lung disease is a key concern.

This monitoring is best coordinated through a metabolic or lysosomal-disease center. Importantly, carriers themselves need no medical surveillance and no restrictions. If you carry one variant and have normal enzyme activity, this monitoring simply does not apply to you.

Prevention here also means preventing affected pregnancies for two-carrier couples, framed as options rather than obligations. These choices include:

• Preconception counseling to understand the risks before pregnancy.
• Carrier testing of a partner to learn whether both partners carry a variant.
• Prenatal diagnosis by chorionic villus sampling or amniocentesis during pregnancy.
• Preimplantation genetic testing (PGT-M), which screens embryos before pregnancy.

Professional guidance now supports offering broad, ancestry-neutral carrier screening to reproductive-age adults, while noting that SMPD1 was historically prominent on Ashkenazi panels. A genetic counselor (NSGC.org) can lay out these choices without pressure so a family can decide what fits their values.

Section recap: Since genotype cannot be changed, early diagnosis, surveillance of the spleen, liver, blood, and lungs, and neutral reproductive options are the real tools; carriers need no surveillance at all.

The Treatment Landscape: Olipudase Alfa (Xenpozyme), Supportive Care, and What Is and Isn’t Treatable

For decades ASMD had only supportive care, so the 2022 arrival of a disease-specific drug was a genuine turning point. Olipudase alfa (Xenpozyme) is a recombinant human acid sphingomyelinase, meaning it supplies a lab-made version of the very enzyme that is missing. The US FDA approved it on 2022-08-31 as the first disease-specific treatment for ASMD, for the non-central-nervous-system manifestations in children and adults. Health Canada authorized it on 2024-02-28 for the same non-brain manifestations. It was also approved in the EU in 2022.

The evidence behind those approvals came from randomized data. The pivotal ASCEND trial was a 52-week, double-blind, placebo-controlled study in 36 adults with chronic ASMD. Its two co-primary endpoints both favored the drug:

ASCEND endpoint (52 weeks)	Olipudase alfa	Placebo
Lung diffusing capacity (percent-predicted DLco)	+22%	+3.0%
Spleen volume	−39%	slight increase

A companion pediatric study, ASCEND-Peds, enrolled 20 children and showed reductions in spleen and liver volume plus better lung function and growth. No treatment-related serious adverse events occurred in the adult trial.

Now the critical limit, stated plainly. Olipudase alfa does not cross the blood-brain barrier, so it does not treat the neurological disease that dominates the severe infantile type A form. The approvals are restricted to non-brain (visceral and lung) manifestations for this exact reason. This is reflected in who was studied. The pediatric ASCEND-Peds trial enrolled only children with chronic visceral (type B) or intermediate disease. No children with the neurodegenerative type A phenotype were included. No therapy reverses brain injury that has already happened. Beyond enzyme therapy, care remains multidisciplinary and supportive, managing low blood counts, lung disease, and liver involvement. Treatment decisions belong to specialists, and a metabolic or lysosomal-disease clinician, coordinated through a genetic counselor (NSGC.org), can advise on a specific case.

Section recap: Olipudase alfa (Xenpozyme), FDA-approved 2022-08-31 and Health Canada-approved 2024-02-28, is a real advance for the non-brain disease of chronic (type B) ASMD, but it does not cross into the brain and does not treat type A neurological disease.

Family Implications and Cascade Testing

A confirmed SMPD1 variant is family news, not just personal news. When a pathogenic variant is found, several relatives may benefit from targeted carrier testing to clarify reproductive risk. This process is called cascade testing, and it typically reaches:

• First-degree relatives — siblings, parents, and children.
• Any reproductive partner, whose status is the most decisive.

One test matters most. A couple’s risk of an affected child hinges on whether both partners carry a pathogenic SMPD1 variant, so a partner’s carrier status is the single most decisive test to pursue. If your partner does not carry a variant, your children cannot develop ASMD, which is often reassuring to learn early.

There is a special reason to reach out in some families. Ashkenazi Jewish founder variants make carrier frequency substantially higher, and expanded Ashkenazi carrier panels are widely offered. Relatives from that background therefore have a higher pre-test chance of being carriers. Raising this with siblings or a partner can feel awkward; a useful frame is that the information is protective, not blaming, and helps everyone plan. NSGC-certified genetic counselors coordinate cascade testing, interpret ambiguous results such as a VUS, and support family communication, and NSGC.org can help you find one.

Section recap: A confirmed variant prompts targeted testing of close relatives and, above all, the reproductive partner, whose status is decisive; Ashkenazi ancestry raises carrier odds, and counselors coordinate the whole cascade process.

Psychosocial Impact and US/Canada Legal Protections: GINA and the Insurance Gap

The emotional weight is real, and so is the worry about insurance, especially when a rare-disease drug can be costly. In the US, the Genetic Information Nondiscrimination Act (GINA, 2008), together with the Affordable Care Act, bars health insurers and employers from using genetic information to discriminate. That covers the two fears many people raise first: losing health coverage or being treated differently at work.

But there is a genuine gap. In the US, GINA does not cover every kind of policy, and Canada takes a different approach:

• US health insurance and employment: protected by GINA plus the ACA.
• US life, disability, and long-term-care insurance: not covered by GINA, so a genetic result could in principle affect these policies.
• Canada, all contracts including insurance: the Genetic Non-Discrimination Act (2017) makes it a crime to require genetic testing or disclosure as a condition of a contract or service.

Canada’s protection is therefore broader. The Supreme Court of Canada upheld the law’s core provisions as valid criminal law in a 2020 decision.

Money worries deserve honesty too. Olipudase alfa is a high-cost specialty biologic given by ongoing infusions. In the US, families often navigate access through private insurance, manufacturer patient-support programs, and Medicaid or Medicare. In Canada, access usually comes through provincial drug programs and case-by-case rare-disease funding.

The human side matters as much as the legal side. Anxiety, family-disclosure stress, and decision fatigue are normal. Patient-advocacy organizations such as the National Niemann-Pick Disease Foundation, and genetic counseling itself, exist partly for this reason. A genetic counselor (NSGC.org) can address both the medical facts and the emotional dimension.

Section recap: GINA and the ACA protect US health insurance and employment but not life, disability, or long-term-care coverage, while Canada’s GNDA (upheld in 2020) is broader; counseling and advocacy groups support the emotional and financial sides alongside the legal facts.

Frequently Asked Questions

Will I get Niemann-Pick disease / ASMD if I carry one SMPD1 variant? Very unlikely. ASMD is autosomal-recessive, so it appears only when a person has two pathogenic variants, one from each parent, and a single carrier stays unaffected. Carrier status affects reproductive planning, not your own health, and a genetic counselor can put that in context.

Will my children inherit Niemann-Pick disease? Only if your reproductive partner also carries a pathogenic SMPD1 variant. If both of you carry one, each pregnancy has a 25% chance of an affected child, about 25 out of 100. If your partner is not a carrier, none of your children can develop the disease. Partner testing is the way to know, and a genetic counselor can arrange it.

What’s the difference between Niemann-Pick type A, type B, and type C? Types A and B are both ASMD, caused by SMPD1 variants, and they span a spectrum from the severe infantile neurovisceral form (type A) to the chronic visceral form (type B). Type C is a genetically separate disease caused by NPC1 or NPC2 variants; it shares only the historical name.

Is there a treatment or cure now that a drug was approved? Olipudase alfa (Xenpozyme) is FDA-approved (2022-08-31) and Health Canada-approved (2024-02-28) for the non-brain manifestations of ASMD, and randomized trials showed it improves lung function and shrinks the spleen. But it does not cross the blood-brain barrier and does not treat the neurological disease of type A. Other care remains supportive and multidisciplinary.

Should I get a second opinion or confirmatory test? Yes, if your result came from a direct-to-consumer panel. Those are limited, screening-only tools, and abnormal findings should be confirmed in a CLIA-certified US lab or accredited Canadian lab. An enzyme assay plus SMPD1 sequencing is the diagnostic pathway, and an NSGC-certified genetic counselor can help you interpret the results.

Summary

Niemann-Pick disease types A and B, now grouped as acid sphingomyelinase deficiency (ASMD), is a rare, autosomal-recessive condition caused by two pathogenic variants in the SMPD1 gene. A single carrier result is a reproductive-planning fact, not a personal diagnosis, and it creates a 25% per-pregnancy risk only when both partners carry a variant. Type A/B (SMPD1) is genetically separate from Niemann-Pick type C (NPC1/NPC2), which shares only the old name. Consumer reports are limited, screening-only panels, so confirmation through an enzyme assay and SMPD1 sequencing in a clinical lab is the real next step.

The treatment landscape changed in 2022. The randomized ASCEND trial supported olipudase alfa (Xenpozyme), which the FDA approved on 2022-08-31 and Health Canada authorized on 2024-02-28 for the non-brain manifestations of ASMD. It improves lung function and shrinks the spleen, but it does not cross the blood-brain barrier and does not treat the neurological disease of type A, and no therapy reverses established brain injury. Otherwise, care is supportive and multidisciplinary, watching the spleen, liver, blood counts, and lungs. On the legal side, GINA protects US health coverage and jobs but leaves a life and disability insurance gap, while Canada’s GNDA is broader. Throughout, an NSGC-certified genetic counselor is the person who turns these facts into a plan that fits your family.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. OMIM #257200 — Niemann-Pick Disease, Type A; NPA. McKusick-Nathans Institute, Johns Hopkins / NCBI. https://www.omim.org/entry/257200
2. OMIM #607616 / *607608 — Niemann-Pick Disease, Type B and SMPD1. McKusick-Nathans Institute, Johns Hopkins / NCBI. https://omim.org/entry/607616
3. Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease. Molecular Genetics and Metabolism. 2017;120(1-2):27-33. https://pubmed.ncbi.nlm.nih.gov/28030910/
4. McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genetics in Medicine. 2013;15(8):618-623. https://www.nature.com/articles/gim20134
5. Wasserstein MP, Lachmann R, Hollak C, et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic ASMD in adults: one-year results (ASCEND). Genetics in Medicine. 2022. https://www.gimjournal.org/article/S1098-3600(22)00716-X/fulltext
6. Diaz GA, Jones SA, Scarpa M, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with ASMD (ASCEND-Peds). Genetics in Medicine. 2021. https://www.gimjournal.org/article/S1098-3600(21)05062-0/fulltext
7. US FDA — Xenpozyme (olipudase alfa-rpcp) prescribing information and approval record; approved 2022-08-31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761261s000lbl.pdf
8. Health Canada — Summary Basis of Decision / Notice of Compliance for Xenpozyme (olipudase alfa); issued 2024-02-28. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1725029128529
9. Genetic Information Nondiscrimination Act (GINA, 2008), EEOC & genome.gov; Canada Genetic Non-Discrimination Act (2017), upheld by the Supreme Court of Canada (2020). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
10. Wang RY, Bodamer OA, Watson MS, Wilcox WR; ACMG Work Group. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genetics in Medicine. 2011;13(5):457-484. https://www.nature.com/articles/gim9134
11. Wasserstein MP, Aron A, Brodie SE, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genetics in Medicine. 2017;19(9):967-974. https://www.nature.com/articles/gim20177
12. Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception (ACMG practice resource). Genetics in Medicine. 2021;23(10):1793-1806. https://www.nature.com/articles/s41436-021-01203-z
13. Richards S, Aziz N, Bale S, et al. Standards and Guidelines for the Interpretation of Sequence Variants (ACMG/AMP). Genetics in Medicine. 2015;17(5):405-424. https://www.nature.com/articles/gim201530
14. National Society of Genetic Counselors (NSGC) — practice guidance on cascade testing, carrier screening, and family communication. https://www.nsgc.org/Policy-Research-and-Publications/Practice-Guidelines

Last updated: 2026-08-03 Author: genelumen editorial team — cross-analyzed and restructured 14 published research sources from peer-reviewed medical literature and public health agencies (tier 1=A / tier 2=B), including NIH/OMIM, FDA, Health Canada, ACMG guidelines, NSGC, and PubMed-indexed publications. This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan). Image: Editorial illustration. Related: Metabolic and Hematologic Genetic Diseases category

🌐 日本語版: ニーマンピック病(ASMD/SMPD1)の遺伝と検査｜「保因者」報告は発症予告ではない